Long-term safety and efficacy of tobramycin in the management of cystic fibrosis

References

• MacKenzieTGiffordAHSabadosaKALongevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registryAnn Intern Med2014161423324125133359
   PubMed Web of Science ®Google Scholar
• Girón MorenoRMSalcedo PosadasAMar Gómez-PunterR[Inhaled antibiotic therapy in cystic fibrosis]Arch Bronchoneumol201147Suppl 61418 Spanish
   PubMedGoogle Scholar
• MossRBLong-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosisChest20021211556311796432
   PubMed Web of Science ®Google Scholar
• McKeageKTobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosisDrugs201373161815182724194436
   PubMed Web of Science ®Google Scholar
• BurnsJLRolainJMCulture-based diagnostic microbiology in cystic fibrosis: can we simplify the complexity?J Cyst Fibros20141311924094376
   PubMed Web of Science ®Google Scholar
• HamptonTHGreenDMCuttingGRThe microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of interventionMicrobiome201421425071935
   PubMed Web of Science ®Google Scholar
• MáizLGirónRMOlveiraCInhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trialsExpert Opin Pharmacother20131491135114923586963
   PubMed Web of Science ®Google Scholar
• FlumePAO’SullivanBPRobinsonKACystic Fibrosis Foundation, Pulmonary Therapies CommitteeCystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung healthAm J Respir Crit Care Med20071761095796917761616
   PubMed Web of Science ®Google Scholar
• EmersonJRosenfeldMMcNamaraSRamseyBGibsonRLPseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatr Pulmonol20023429110012112774
   PubMed Web of Science ®Google Scholar
• SimmondsNJMacneillSJCullinanPHodsonMECystic fibrosis and survival to 40 years: a case-control studyEur Respir J20103661277128320378603
   PubMed Web of Science ®Google Scholar
• UK Cystic Fibrosis Trust Antibiotic Working GroupAntibiotic Treatment for Cystic Fibrosis3rdKent, UKUK Cystic Fibrosis Trust2009
   Google Scholar
• StephensDGareyNIslesALevisonHGoldREfficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosisPediatr Infect Dis1983232092116408619
   PubMedGoogle Scholar
• RatjenFBrockhausFAngyalosiGAminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a reviewJ Cyst Fibros20098636136919747887
   PubMed Web of Science ®Google Scholar
• LamJVaughanSParkinsMDTobramycin inhalation powder (TIP): an efficient treatment strategy for the management of chronic Pseudomonas aeruginosa infection in cystic fibrosisClin Med Insights Circ Respir Pulm Med20137617724324354
   PubMedGoogle Scholar
• European Medicines AgencyAnnex I: Summary of Product CharacteristicsLondon, UKEuropean Medicines Agency2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002155/WC500110921.pdfAccessed July 20, 2014
   Google Scholar
• PooleKAminoglycoside resistance in Pseudomonas aeruginosaAntimicrob Agents Chemother200549247948715673721
   PubMed Web of Science ®Google Scholar
• PooleKMultidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organismsJ Mol Microbiol Biotechnol20013225526411321581
   PubMed Web of Science ®Google Scholar
• WolterDJSmith-MolandEGoeringRVHansonNDListerPDMultidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospitalDiagn Microbiol Infect Dis2004501435015380277
   PubMed Web of Science ®Google Scholar
• StratevaTYordanovDPseudomonas aeruginosa – a phenomenon of bacterial resistanceJ Med Microbiol200958Pt 91133114819528173
   PubMed Web of Science ®Google Scholar
• HøibyNUnderstanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapiesJ Cyst Fibros20021424925415463822
   PubMedGoogle Scholar
• SmithALRamseyBWHedgesDLSafety of aerosol tobramycin administration for 3 months to patients with cystic fibrosisPediatr Pulmonol1989742652712515523
   PubMed Web of Science ®Google Scholar
• Le BrunPPde BoerAHGjaltemaDHagedoornPHeijermanHGFrijlinkHWInhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizerInt J Pharm1999189220521410536249
   PubMed Web of Science ®Google Scholar
• RamseyBWPepeMSQuanJMIntermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study GroupN Engl J Med1999340123309878641
   PubMed Web of Science ®Google Scholar
• QuittnerALBuuAEffects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infectionPediatr Pulmonol200233426927611921456
   PubMed Web of Science ®Google Scholar
• MurphyTDAnbarRDLesterLATreatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung diseasePediatr Pulmonol200438431432015334509
   PubMed Web of Science ®Google Scholar
• LenoirGAntypkinYGMianoAEfficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosaPaediatr Drugs20079Suppl 1112017536871
   PubMedGoogle Scholar
• ChuchalinACsiszérEGyurkovicsKA formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter studyPaediatr Drugs20079Suppl 1213117536872
   PubMedGoogle Scholar
• MazurekHLenoirGPelikanLHead-to-head comparison of two inhaled tobramycin solutions in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (Pa) infection [abstract]J Cyst Fibros201110Suppl 1S28
   Google Scholar
• KonstanMWGellerDEMinićPBrockhausFZhangJAngyalosiGTobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trialPediatr Pulmonol201146323023820963831
   PubMed Web of Science ®Google Scholar
• KonstanMWFlumePAKapplerMSafety, efficacy and the convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trialJ Cyst Fibros2011101546121075062
   PubMed Web of Science ®Google Scholar
• GalevaIKonstanMWHigginsMA challenging double-blind placebo-controlled study of tobramycin inhalation powder in cystic fibrosis: results of the EDIT trial [abstract]J Cyst Fibros201211Suppl 1S12
   Google Scholar
• QuittnerALHigginsMAngyalosiGBrockhausFThomasKZhangJTrends in health-related quality of life (HRQoL) in cystic fibrosis with tobramycin inhalation powder: the EDIT trial [abstract]J Cyst Fibros201211Suppl 1S73
   Google Scholar
• MazurekHChironRPelikanLComparison of two inhaled tobramycin solutions in cystic fibrosis patients with Pseudomonas aeruginosa infection: results in different age subgroups [abstract]J Cyst Fibros201110Suppl 1S28
   Google Scholar
• GellerDEWeersJHeuerdingSDevelopment of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technologyJ Aerosol Med Pulm Drug Deliv201124417518221395432
   PubMed Web of Science ®Google Scholar
• GellerDEKonstanMWSmithJNoonbergSBConradCNovel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safetyPediatr Pulmonol200742430731317352404
   PubMed Web of Science ®Google Scholar
• NewhouseMTHirstPHDudduSPInhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteersChest2003124136036612853545
   PubMed Web of Science ®Google Scholar
• TreggiariMMRetsch-BogartGMayer-HamblettNEarly Pseudomonas Infection Control (EPIC) InvestigatorsComparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosisArch Pediatr Adolesc Med2011165984785621893650
   PubMedGoogle Scholar
• RatjenFMunckAKhoPShort and long-term efficacy of inhaled tobramycin in early P. aeruginosa infection: the ELITE studyPediatric Pulmonology200843Suppl 31319320
   Google Scholar
• RatjenFMunckAKhoPAngyalosiGELITE Study GroupTreatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trialThorax201065428629119996339
   PubMed Web of Science ®Google Scholar
• AssaelBMPresslerTBiltonDAZLI Active Comparator Study GroupInhaled aztreonam lysine vs inhaled tobramycin in cystic fibrosis: a comparative efficacy trialJ Cyst Fibros201312213014022985692
   PubMed Web of Science ®Google Scholar
• StockmannCSherwinCMAmpofoKSpigarelliMGDevelopment of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosisTher Adv Respir Dis201481132124334337
   PubMed Web of Science ®Google Scholar
• WatersVRatjenFInhaled liposomal amikacinExpert Rev Respir Med20148440140924882271
   PubMed Web of Science ®Google Scholar
• HeinzlBEberEOberwaldnerBHaasGZachMSEffects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot studyPediatr Pulmonol2002331323711747258
   PubMed Web of Science ®Google Scholar
• RatjenFDöringGNikolaizikWHEffect of inhaled tobramycin on early Pseudomonas aeruginosa conolisation in patients with cystic fibrosisLancet2001358928698398411583754
   PubMed Web of Science ®Google Scholar
• Barrio Gómez de AgüeroMIGarcía HernándezGGartnerSGrupo de Trabajo de Fibrosis QuísticaProtocol for the diagnosis and follow up of patients with cystic fibrosisAn Pediatr (Barc)2009713250264 Spanish19643690
   PubMed Web of Science ®Google Scholar
• CantónRMaizLEscribanoAConsenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quísticaArch BonconeumolIn press2015 Spanish
   Google Scholar
• RazviSQuittellLSewallAQuintonHMarshallBSaimanLRespiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005Chest200913661554156019505987
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis FoundationPatient Registry: Annual Data Report 2009Bethesda, MDCystic Fibrosis Foundation2007
   Google Scholar
• MogayzelPJNaureckasETRobinsonKAPulmonary Clinical Practice Guidelines CommitteeCystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung healthAm J Respir Crit Care Med2013187768068923540878
   PubMed Web of Science ®Google Scholar